Skip to content

NASDAQ · micro · thesis board

SLDB Solid Biosciences

AAV-SLB101 microdystrophin gene therapy

View race

Thesis

Editorial summary — not a primary filing

Next-gen DMD gene therapy SGT-003 aims for differentiated expression; binary clinical readouts ahead.

Next gate

2027-03-01EstimatedPh2 readout

Dose expansion data

200 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~5 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~358d)100%
Days to gate (200d)56%
Show math

$165M cash ÷ $14M/mo burn ≈ 358 days. Source: curated SEC quarter figures.

Cash $165M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
SRPTApprovedokCAPRFiledokRCKTPh2ok

Risks

  • Binary trial risk
  • Runway vs peers
  • Immunogenicity
  • Competitive lag

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT06138639as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01